Literature DB >> 23729372

Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.

Jessica A Reese1, Darrshini S Muthurajah, Johanna A Kremer Hovinga, Sara K Vesely, Deirdra R Terrell, James N George.   

Abstract

BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) associated with severe, acquired ADAMTS13 deficiency is uncommonly reported in children. The incidence, demographic, and clinical features of these children, compared to adults, have not been described. PROCEDURES: This study focused on children (<18 years old) and adults with TTP associated with severe, acquired ADAMTS13 deficiency, defined as activity <10%. The incidence rates for TTP in children and adults were calculated from patients enrolled in the Oklahoma TTP-HUS (Hemolytic-Uremic syndrome) Registry, 1996-2012. To describe demographic and clinical features, children with TTP were also identified from a systematic review of published reports and from samples sent to a reference laboratory for analysis of ADAMTS13.
RESULTS: The standardized annual incidence rate of TTP in children was 0.09 × 10(6) children per year, 3% of the incidence rate among adults (2.88 × 10(6) adults per year). Among the 79 children who were identified (one from the Oklahoma Registry, 55 from published reports, 23 from the reference laboratory), TTP appeared to be more common among females, similar to the relative increased frequency of women among adults with TTP, and more common in older children. Clinical data were available on 52 children; the frequency of severe renal failure, relapse, treatment with rituximab, and systemic lupus erythematosus in these children was similar to adults with TTP.
CONCLUSIONS: TTP associated with severe, acquired ADAMTS13 deficiency is uncommon in children. The demographic and clinical features of these children are similar to the features of adults with TTP.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  TTP; children; disparities; incidence; thrombotic thrombocytopenic purpura

Mesh:

Substances:

Year:  2013        PMID: 23729372     DOI: 10.1002/pbc.24612

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  47 in total

Review 1.  Clinical and laboratory diagnosis of TTP: an integrated approach.

Authors:  Thita Chiasakul; Adam Cuker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  TTP: long-term outcomes following recovery.

Authors:  James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin.

Authors:  Jessica A Reese; Daniel W Bougie; Brian R Curtis; Deirdra R Terrell; Sara K Vesely; Richard H Aster; James N George
Journal:  Am J Hematol       Date:  2015-02-25       Impact factor: 10.047

4.  Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura.

Authors:  Bowie Han; Evaren E Page; Lauren M Stewart; Cassandra C Deford; James G Scott; Lauren H Schwartz; Jedidiah J Perdue; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Am J Hematol       Date:  2015-05-28       Impact factor: 10.047

Review 5.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 6.  Understanding thrombotic microangiopathies in children.

Authors:  Bérangère S Joly; X Long Zheng; Agnès Veyradier
Journal:  Intensive Care Med       Date:  2018-01-24       Impact factor: 17.440

Review 7.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

8.  Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.

Authors:  Sabrina Mariani; Silvia M Trisolini; Saveria Capria; Maria L Moleti; Marta Chisini; Giancarlo Ferrazza; Mahnaz Shafii Bafti; Maria A Limongiello; Eleonora Miulli; Flora Peyvandi; Robin Foà; Anna M Testi
Journal:  Haematologica       Date:  2018-03       Impact factor: 9.941

9.  Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience.

Authors:  James N George; Steven A Sandler; Joanna Stankiewicz
Journal:  Blood Adv       Date:  2017-10-30

10.  Acute kidney injuries induced by thrombotic microangiopathy following severe hemorrhage in puerperants: a case series and literature review.

Authors:  Xu Wang; Chun-Yan Liu; Yue Yang; Gu-Ming Zou; Li Zhuo; Su-Hui Han; Wen-Ge Li
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.